

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

65. (currently amended) A pharmaceutical composition comprising a monovalent antibody fragment which binds *in vivo* to human platelet glycoprotein GPIb without incurring thrombocytopenia and a pharmaceutically acceptable carrier.

66. (previously presented) The pharmaceutical composition according to claim 65, wherein said fragment is an Fab fragment or a single variable domain.

67. (cancelled)

68. (cancelled)

69. (cancelled)

70. (currently amended) The pharmaceutical composition according to claim 65, wherein the variable region of said fragment comprises a sequence having at least 60% ~~sequence identity with SEQ ID NO: 4~~ 80% sequence identity with SEQ ID NO: 4 within the CDR regions as identified in Figure 13.

71. (currently amended) The pharmaceutical composition according to claim 65, wherein said monovalent antibody fragment is obtained from a monoclonal antibody is produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

72. (previously presented) A monovalent antibody fragment which binds *in vivo* to human platelet glycoprotein GPIb, and prevents the binding of von Willebrand factor to human platelet glycoprotein GPIb.
73. (previously presented) The fragment of claim 72, which is an F_{ab} fragment or a single variable domain.
74. (currently amended) The fragment of claim 72, which inhibits platelet adhesion ~~and/or inhibits platelet activation under high shear conditions and/or inhibits platelet aggregation~~ under high shear conditions.
75. (currently amended) The fragment of claim 72, wherein said monovalent antibody fragment is obtained from a monoclonal antibody is produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.
76. (cancelled)
77. (cancelled)
78. (cancelled)
79. (cancelled)
80. (previously presented) A monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

81. (previously presented) A cell line, capable of producing an antibody directed against GP1b deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.
82. (currently amended) A humanized antibody fragment derivable from the monoclonal antibody cell line of claim ~~81~~80.
83. (new) The antibody fragment of claim 72, wherein the variable regions of said fragment comprise a sequence having at least 80% sequence identity with SEQ ID NO: 4 within the CDR regions as identified in Figure 13.